Inhaled Investigational Medication for Cystic Fibrosis

Trial Objective

The purpose of this study is to better understand how an investigational medication, QBW276, affects people with cystic fibrosis (CF).

Inhaled Investigational Medication for Cystic Fibrosis

In addition to determining QBW276’s safety and tolerability, the study will examine how the body responds to the drug. QBW276 is breathed through the mouth. It has not been approved by the Food and Drug Administration (FDA) and is currently not available for prescription or purchase. To date, 76 healthy volunteers have received inhaled QBW276 in clinical studies. Overall, QBW276 has been found to be generally safe and well tolerated without any significant adverse effects.


This trial is active and currently recruiting.

How to Participate

For more information, call 303.270.2321 or complete the form below. 

Who Can Participate

Adults with a confirmed diagnosis of cystic fibrosis are eligible to participate.

Estimated Time Commitment

1 month, 1 1/2 months or 4 months

This study is made up of three separate groups, or cohorts, of participants. Participation time is as follows: Cohort 1 – one month, Cohort 2 -- one and a half months, Cohort 3 -- four months. Cohort 1 is complete.

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

Novartis Pharmaceuticals Corporation




Any Gender

Principal Investigators

Request More Information